Vyleesi (bremelanotide) is an agonist of melanocortin receptor given to treat premenopausal women experiencing acquired, generalized hypoactive sexual desire disorder (HSDD) as marked by low sexual desire that produces agony or interpersonal struggle which is not because of a co-existing physical or emotional condition, difficulties among the relationship, or the influences of a medicine or drug material.